Eden Research plc Appointment of Commercial Director (8889B)
June 12 2019 - 1:00AM
UK Regulatory
TIDMEDEN
RNS Number : 8889B
Eden Research plc
12 June 2019
12 June 2019
Eden Research plc
("Eden" or "Company")
Appointment of Commercial Director
Eden Research plc (AIM: EDEN), the AIM listed company that
develops and supplies breakthrough biopesticide products and
natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries, is
pleased to announce the appointment of Robert ("Rob") Cannings to
the new role of Commercial Director, with effect from 12 June
2019.
For the last ten years, Rob has worked in an entrepreneurial
environment at the cutting edge of the agricultural biologicals
industry and, prior to that, in key positions with mainstream
conventional agrochemicals. With this extensive knowledge, Rob has
been effective in developing strategies and market positioning for
new conventional and biological products and using this to
prioritise the development and commercialisation of new crop
protection products globally.
Rob has been Global Product Manager for Chemtura, AgraQuest, and
Bayer CropScience where he created global growth and pricing
strategies for conventional and biological products and where he
was instrumental in the sale of AgraQuest to Bayer for more than
$425m. Most recently, Rob served as Commercial Director at Plant
Health Care with responsibility for Europe, the Middle East, Africa
and Asia.
Sean Smith, Chief Executive Officer of Eden, said: "We are
pleased to welcome Rob to the team at Eden. Rob's detailed
understanding of the conventional pesticide and biocontrol products
markets globally will be a key asset for the company as it works
towards delivering on its ambitious growth plans. His hands-on
experience with the entire process from research and development
through to product commercialisation, marketing and sales, will be
invaluable to Eden as we accelerate our growth plans by expanding
our regulatory and commercial footprint.
Rob's appointment is considered a key hire within the Company's
previously announced plans to grow its in-house capabilities
through the recruitment of high-calibre staff with relevant
experience and track records of demonstrable success."
For further information contact:
Eden Research plc www.edenresearch.com
Sean Smith
Alex Abrey 01285 359 555
Shore Capital (Nomad) 020 7408 4090
Stephane Auton / Patrick Castle
Powerscourt (Financial PR) 020 7250 1446
Nick Dibden eden@powerscourt-group.com
Jana Tsiligiannis
Notes:
Eden Research is a technology development and commercialisation
company with intellectual property and expertise in encapsulation,
terpenes and environmentally friendly technologies to provide
naturally occurring solutions for the global agrochemicals, animal
health, and consumer product industries.
Eden's encapsulation technology harnesses the biocidal efficacy
of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. The technology uses
yeast cells that are a by-product of numerous commercial production
processes to deliver a slow release of natural compounds for
agricultural and non-agricultural uses. Terpenes are already widely
used in the food flavouring, cosmetics and pharmaceutical
industries.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Eden's platform encapsulation technology provides a
unique, environmentally friendly solution to these problems and
enables terpenes to be used as effective, low-risk
agrochemicals.
Eden is developing these technologies through innovative
research and a series of commercial production, marketing and
distribution partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of GBP13m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into commercial agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, Mevalone, were approved as new ingredients for
use in plant protection products. This represented a major
milestone in the commercialisation of Eden's technology and is a
significant accomplishment for any company. To illustrate this
point, one should note that in all of 2013, Eden's approvals
represented 3 of only 10 new active ingredients approved by the
EC.
Mevalone has been authorised for sale in Kenya, Malta, Greece,
Bulgaria, Spain, Italy, France, Cyprus, Albania, Portugal and
Macedonia.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
For more information about Eden, please visit:
www.edenresearch.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUARURKUANAUR
(END) Dow Jones Newswires
June 12, 2019 02:00 ET (06:00 GMT)
Eden Research (LSE:EDEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eden Research (LSE:EDEN)
Historical Stock Chart
From May 2023 to May 2024